SARS-CoV-2 infection was associated with rapid growth of plaque in the coronary arteries and an increased risk of cardiovascular events compared to noninfected patients.
The latest Phase 2/3 trial results show NVX-CoV2601 outperforms its predecessor, offering protection against emerging COVID-19 strains.
The successful implementation of AI into trying to combat resistance will require broader integration efforts, training, and regulatory frameworks.
European agencies warn that non-medical fungicide use may be fueling resistance in A fumigatus, a mold responsible for severe human infections.
The agency pointed out that pathogens such as Klebsiella pneumoniae and Escherichia coli (E coli) are problematic for healthcare systems and the general public across Europe.
Robert Allen, MD, on variant monitoring, antibody development, and the company's long-term approach to patient care.
Levofloxacin was associated with statistically significant reduction in tuberculosis developing in household contacts of persons with multidrug- resistant TB in a meta-analysis, but not in the constituent controlled trials.
Sasirekha Ramani, PhD on creating a broad-spectrum antiviral that could be effective in various clinical settings, especially given the emergence of new and more dominant strains.
Children with invasive candidiasis had successful outcome whether IV antifungal treatment was completed or converted to enteral to reduce risk of infusion site infections and costs.
Robert Allen, PhD, discusses how Pemgarda’s stability in targeting the spike protein's receptor-binding domain offers crucial protection, including immunocompromised individuals.
Prashant Kumar’s study on indoor air quality aboard cruise ships highlights the critical role of ventilation and masking in reducing infection risks.
Cabotegravir (Vocabria) + rilpivirine (Rekambys) is the first and only complete long-acting injectable regimen for the treatment of HIV.
Kansas is experiencing the largest tuberculosis outbreak in decades, a preview into vaccines and treatments up for FDA approval this winter/spring, and more.
The company said its oral therapy, S-337395, achieved a 88.94% reduction in viral load.
Gregory Fox, PhD outlines the trial's challenges, the impact of combining results with the TB Champ trial, and the role of collaboration in strengthening research outcomes.
This is the second in a series looking at the intersection of government and public health. In this segment, Contagion Editor-in-Chief Jason Gallagher, FCCP, FIDP, FIDSA, BCPS, discusses the WHO pullout, and the pauses on federal communication and research grants.
Alejandro Krolewiecki, MD discusses the path to regulatory approval, collaboration with global health organizations, and the role of partnerships in scaling up the new treatment for neglected tropical diseases.
Investigators developed a novel prognostic model around this subset of patients treated for this fungal infection.
Gregory Fox, PhD discusses the V Quinn trial's results, exploring levofloxacin’s role in reducing TB incidence and the study's approach to combining data with the TB Champ trial.
Biocontainment, including the most recent threat of highly pathogenic avian influenza, demands we continue to finance research, and continue cooperation with important organizations like the WHO.
GAFFI is addressing fungal diagnostic gaps by raising awareness, implementing models, and advocating for resource shifts, despite challenges in funding, infrastructure, and political support.
Intravenous (IV) push is an attractive option to administer antimicrobial therapy to patients in an efficient and effective manner in a variety of clinical settings. While many advantages to IV push administration exist, clinicians should be mindful of available literature regarding safety profiles, pharmacokinetic/pharmacodynamic characteristics, and clinical data for IV push antimicrobial administration prior to utilizing it in specific patient populations.
Alejandro Krolewiecki, MD, discussed testing a combination of albendazole and ivermectin to improve treatments for neglected tropical diseases.
The fully cooked frozen product was not recalled because the product can no longer be purchased. This does apply to consumers who have the product at home.
James F Cummings, MD discusses phase 2b trial Phase 2b trial expansion focusing on safety, efficacy, and immune response for Vaxart’s investigational oral vaccine.
Oropouche fever, primarily found in Central and South America and the Caribbean, has seen a dramatic increase in cases in Brazil.
Vaccines and treatments are up for approval in early to mid-2025, including a chikungunya vaccine, a meningococcal vaccine, a monoclonal antibody for RSV, and more.
The outbreak is currently concentrated in 2 counties in the state, Wyandotte and Johnson.
Research into new antifungal treatments, including drugs in phase two and three trials, offers hope for patients who do not respond to current therapies.
Wendy Dann has MS and describes her experience with a copay assistance program that provides insurers with additional revenue, but does not go towards her deductible.
